Advertisement

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Welcome and Introduction to Vi3C

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement

Jul

21

Today In Oncology

Integrating Environmental Health Into Pediatric Cancer Care May Improve Outcomes

Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types

AMP Recognizes NCI Pathologist With Award for Excellence in Molecular Diagnostics

Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant

Long-Term Outcomes With SABR in Primary Kidney Cancer

Advertisement

© 2026 HSP News Service, L.L.C.